Summary of Study ST001473

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000993. The data can be accessed directly via it's Project DOI: 10.21228/M8BH7T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001473
Study TitleMetabolomics of lung injury after allogeneic hematopoietic cell transplantation - Spleen DI-FTMS
Study Typepreliminary data
Study SummaryAllogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment option for a variety of hematological malignancies. Interactions between the donor immune system and the patient tissue result in a disease, called GVHD. The pathophysiology of acute GVHD can be hypothesized in three sequential phases: cytokine storm and activation of the antigen-presenting cells (APC), donor T cell activation and effector cell phase. Idiopathic pneumonia syndrome (IPS) is one of the most deleterious complications after allogeneic HCT and is considered not only to be related to conditioning regimen toxicity but also represents an end organ damage caused by allo-reactive T cells, therefore making the lung susceptible to a two-pronged attack, one of which overlaps with GVHD causing other target organ injury. IPS results in mortality of up to 90% of patients. We will use a murine model of IPS and GVHD which is well established in our group, and in which disease evolves either across disparities in major histocompatibility complex (MCH) class I and II, minor histocompatibility antigens (miHags) or both. Metabolomics changes following syngeneic and allogeneic HCT at post-transplantation Days +7 (cytokine storm phase) and Days +42 (cellular effector phase) are compared to baseline wild-type (naive) controls. Prior to analysis, naïve - and experimental mice (N=3 from each group) were fed with semi-liquid diet supplemented with tracers (13C6-glucose ) over 24 hours. At the end of 7 days or 42 days, respectively, feces and aGVHD target organs (colon, liver and lung) were collected from all groups and further processed and / or analyzed. We expect to reveal metabolic pathways affected after allo-HCT which contribute to immune cell mediated lung injury (IPS) and will potentially identify different metabolic pathways in other GVHD target organs.
Institute
University of Kentucky
DepartmentMCC
Last NameHildebrandt
First NameGerhard
AddressCTW-453, 900 South Limestone street. UKY. Lexington, Kentucky-40536
Emailgerhard.hildebrandt@uky.edu
Phone800-333-8874
Submit Date2020-08-22
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2020-09-10
Release Version1
Gerhard Hildebrandt Gerhard Hildebrandt
https://dx.doi.org/10.21228/M8BH7T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000993
Project DOI:doi: 10.21228/M8BH7T
Project Title:Metabolomics of lung injury after allogeneic hematopoietic cell transplantation
Institute:University of Kentucky
Department:Markey Cancer Center
Last Name:Hildebrandt
First Name:Gerhard
Address:Gerhard C. Hildebrandt, MD, Room no. CC401A, Ben Roach Building, Markey Cancer Center University of Kentucky, Lexington, 40536
Email:gerhard.hildebrandt@uky.edu
Phone:800-333-8874

Subject:

Subject ID:SU001547
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Protocol
SA12455308_C1-2_Spleen_allogenic_42days70427_UKy_GCH_rep2-lipidallogenic
SA12455413_C1-1_Spleen_allogenic_7days70427_UKy_GCH_rep1-lipidallogenic
SA12455507_C1-1_Spleen_allogenic_42days70427_UKy_GCH_rep1-lipidallogenic
SA12455615_C1-20_Spleen_allogenic_7days70427_UKy_GCH_rep3-lipidallogenic
SA12455714_C1-2_Spleen_allogenic_7days70427_UKy_GCH_rep2-lipidallogenic
SA12455809_C2-0_Spleen_allogenic_42days70427_UKy_GCH_rep1-lipidallogenic
SA12455901_A0_Spleen_naive_0days70427_UKy_GCH_rep1-lipidnaive
SA12456003_A2_Spleen_naive_0days70427_UKy_GCH_rep3-lipidnaive
SA12456102_A1_Spleen_naive_0days70427_UKy_GCH_rep2-lipidnaive
SA12456206_B2_Spleen_syngenic_42days70427_UKy_GCH_rep3-lipidsyngenic
SA12456312_B1-2_Spleen_syngenic_7days70427_UKy_GCH_rep3-lipidsyngenic
SA12456404_B0_Spleen_syngenic_42days70427_UKy_GCH_rep1-lipidsyngenic
SA12456505_B1_Spleen_syngenic_42days70427_UKy_GCH_rep2-lipidsyngenic
SA12456610_B1-0_Spleen_syngenic_7days70427_UKy_GCH_rep1-lipidsyngenic
SA12456711_B1-1_Spleen_syngenic_7days70427_UKy_GCH_rep2-lipidsyngenic
Showing results 1 to 15 of 15

Collection:

Collection ID:CO001542
Collection Summary:Mouse is sacrificed and tissues are harvested.
Collection Protocol ID:mouse_tissue_collection
Sample Type:Multiple tissues

Treatment:

Treatment ID:TR001562
Treatment Summary:Mouse with allogenic bone marrow transplant. Fed with semi-liquid diet supplemented with fully labeled glucose for 24 hours before harvest. Mouse with no treatment. Fed with semi-liquid diet supplemented with fully labeled glucose for 24 hours before harvest. Mouse with syngenic bone marrow transplant. Fed with semi-liquid diet supplemented with fully labeled glucose for 24 hours before harvest.
Treatment Protocol ID:allogenic naive syngenic

Sample Preparation:

Sampleprep ID:SP001555
Sampleprep Summary:Frozen tissue is ground in a SPEX grinder under liquid nitrogen to homogenize the sample. Lipid extraction from homogenate. Protein extraction and quantification. Tissue is frozen in liquid nitrogen to stop metabolic processes.
Sampleprep Protocol ID:lipid_extraction; frozen_tissue_grind; tissue_quench; protein_extraction
Sampleprep Protocol Filename:4B_Extract_Polar_Lipid_Prot_Fan_070417.pdf
4D7Jun4_Fan_Prot_Quant.pdf

Combined analysis:

Analysis ID AN002449
Analysis type MS
Chromatography type None (Direct infusion)
Chromatography system None
Column None
MS Type ESI
MS instrument type FTMS
MS instrument name Orbitrap Fusion
Ion Mode POSITIVE
Units peak_height

Chromatography:

Chromatography ID:CH001794
Chromatography Summary:None
Instrument Name:None
Column Name:None
Chromatography Type:None (Direct infusion)

MS:

MS ID:MS002272
Analysis ID:AN002449
Instrument Name:Orbitrap Fusion
Instrument Type:FTMS
MS Type:ESI
MS Comments:Measurements made using direct infusion (nano-electrospray) FTMS.
Ion Mode:POSITIVE
  logo